“Arab Health is an excellent venue for meeting and helping to qualify
distribution partners for the Middle East, North Africa and South Asia,
important geographic markets for LuViva,” said Mark L. Faupel, Ph.D.,
CEO and President of Guided Therapeutics. “LuViva provides distributors
in the gynecology space with an innovative and exciting product that is
simple to use, cost effective and features a device and
single-patient-use disposable business model to attract new and
recurring business.”

LuViva currently has marketing approval from Health Canada and received
its first CE Mark, an ISO 60601 Edition 2 Notification, in July. Guided
Therapeutics was awarded ISO 13485 certification in January 2011.
Additionally, LuViva has been under U.S. Food and Drug Administration
Premarket review since September 23, 2010. After meetings with the FDA,
the Company filed an amended PMA application with the agency in November
2012.

About Arab Health

Arab Health, now in its 38th year, is the world's longest running
healthcare exhibition and congress, taking place every January in Dubai.
With the Middle East healthcare industry worth an estimated $80 billion
per year, Arab Health is truly at 'The Heart of Global Healthcare.' For
more information, visit www.arabhealthonline.com.

Some key facts about Arab Health:

3,500 Exhibitors

32 Country Pavilions

83,278 Attendees

142 Countries Represented

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which eliminates costly, painful and unnecessary testing.
LuViva is designed for use with women who have undergone initial
screening and are called back for follow up with a colposcopy
examination, which in many cases, involves taking a biopsy of the
cervix. The device is used in conjunction with the LuViva®
Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a
rapid and painless testing platform for the early detection of disease
based on its patented biophotonic technology that utilizes light to
detect disease at the cellular level. The Company’s first planned
product is the LuViva®Advanced Cervical Scan, a non-invasive
device used to detect cervical disease instantly and at the point of
care. In a multi-center clinical trial, with women at risk for cervical
disease, the technology was able to detect cervical cancer up to two
years earlier than conventional modalities, according to published
reports. Guided Therapeutics has also entered into a partnership with
Konica Minolta to develop a non-invasive test for the early detection of
esophageal cancer using the technology platform. For more information,
visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use. LuViva, the wave logo and "Early detection,
better outcomes" are registered trademarks owned by Guided Therapeutics,
Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the uncertainty of capital to develop products, the
uncertainty of regulatory approval of products, dependence on licensed
intellectual property, as well as those that are more fully described
from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2011,
and subsequent quarterly reports.